Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CAMX
Cambiar Aggressive Value ETF
34.7
9
USD
+0.01%
Market Price
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.84%
Monthly Change
+3.54%
6 month change
+4.95%
Year Change
+6.75%
Previous Close
34.7
9
Open
34.8
4
Low
34.7
9
High
34.8
4
Markets
US ETFs
CAMX
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
UBER
UBER TECHNOLOGIES, INC.
3.22 M
45.76 K
4.73%
Airbus SE
3.14 M
53.72 K
4.61%
BMY
BRISTOL-MYERS SQUIBB COMPANY
3.04 M
46.56 K
4.47%
ELV
ELEVANCE HEALTH, INC.
3.01 M
8 000.00
4.42%
LUV
SOUTHWEST AIRLINES CO.
2.79 M
62.07 K
4.10%
CME
CME GROUP INC.
2.77 M
10.35 K
4.07%
UNP
UNION PACIFIC CORPORATION
2.76 M
9 450.00
4.06%
Nintendo Co., Ltd.
2.70 M
228.80 K
3.97%
DAL
DELTA AIR LINES, INC.
2.64 M
30.24 K
3.89%
ALGN
ALIGN TECHNOLOGY, INC.
2.47 M
14.62 K
3.63%
MDT
MEDTRONIC PUBLIC LIMITED COMPANY
2.45 M
28.75 K
3.61%
SHIMANO INC.
2.36 M
188.00 K
3.47%
A
AMRZ
Amrize AG
2.34 M
47.75 K
3.43%
AMZN
AMAZON.COM, INC.
2.31 M
8 500.00
3.39%
GOOGL
ALPHABET INC.
2.21 M
6 196.00
3.24%
NTNX
NUTANIX, INC.
2.15 M
36.51 K
3.17%
ICE
INTERCONTINENTAL EXCHANGE, INC.
2.03 M
13.33 K
2.99%
APTV
APTIV PLC
2.02 M
35.81 K
2.97%
OMC
OMNICOM GROUP INC.
1.97 M
25.00 K
2.89%
ZG
ZILLOW GROUP, INC.
1.93 M
55.71 K
2.84%
1
2
News
Uber Axes 3,300 Jobs to Build Its Autonomous Future - Uber Technologies (NYSE:UBER)
Camurus reports Q4 revenue miss, lowers 2026 outlook
FDA accepts Camurus’ resubmission for acromegaly treatment Oclaiz
Camurus Q3 2025 slides: Revenue up 18% but stock dips on lowered guidance
Camurus cuts 2025 revenue forecast as Buvidal sales miss estimates
Camurus Q2 2025 slides reveal 52% revenue surge and key regulatory milestones
Earnings call transcript: Camurus AB Q2 2025 earnings beat expectations
Camurus Q2 2025 slides: Record revenue and profit amid product portfolio expansion
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal ® incretins
Camurus Q1 2025 slides: record profitability despite market challenges